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respectively (P< .05 vs placebo). CONCLUSIONS: These findings suggest that PHEN/
TPM ER-enhanced WL is associated with a reduction in annual medication costs vs 
placebo in patients with MetS.
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OBJECTIVES: Immunobiologicals (IMB) should only be used as a second line treatment 
of rheumatic diseases because of its potential risks and high cost. This study aimed 
to outline the profile of IMB use by the analyses of pharmacotherapeutic and phar-
macoeconomic indicators derived from a cohort of rheumatic patients. METHODS: 
This was a prospective observational exploratory study that analyzed data from the 
follow-up charts of 204 patients in treatment with IMB, previously authorized by rheu-
matologists and then monitored by a Pharmaceutical Auditing Clinical Management 
Program of a Health Insurance Provider in Fortaleza, Brazil, from March-2012 to 
September-2014. For the pharmacotherapeutic and economic analysis, the follow-
ing indicators were used: “Most used IMB” “ indication of the IMB therapy”, “route of 
administration” and “direct cost”. For calculation of the costs, the electronic source 
Brasíndice was used. RESULTS: The most common indications for IMB use were 
rheumatoid arthritis 46.57 % (95/204) and ankylosing spondylitis 41.67% (85/204). 
The intravenous route (IV) was more frequent, 63 % (158/251), when compared to the 
subcutaneous (SC), 37 % (93/251). The main IV IMB was infliximab, 37.27 % (81/251). 
The most used SC IMB and higher proportional increase prescriptive was adalimumab 
15.94% (40/251). The IMB with higher direct cost was infliximab, U$ 41,147.52 per 
capita. The cumulative global cost the immunobiological therapy during the period 
of study was U$6,366,673.33 as adjusted by weight. CONCLUSIONS: Monitoring of 
patients using IMB through a multidisciplinary team is an important clinical manage-
ment tool, enabling the development of strategies for the rationalization of future 
interventions and reduction of its high cost.
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OBJECTIVES: To quantify the clinical and economic benefits of weight loss among 
obese adults in the U.S. and how benefits vary across subsets of the obese popula-
tion. METHODS: A validated, Markov-based microsimulation model was used to sim-
ulate 10-year health and economic outcomes for different subsets of the obese adult 
population, with sample populations drawn from the 2005-2012 National Health and 
Nutrition Examination Surveys. Obese subgroups included those with prediabetes; 
ages 20-44, 45-64, and 65 and above; and obese category I, II, and III cohorts. Prediction 
equations for disease onset and economic outcomes come from published literature 
and original research. The model predicts direct and indirect economic outcomes 
from payer, employer, and societal perspectives. RESULTS: The present value (3% 
discount rate) of simulated medical savings associated with modest 5% weight among 
obese adults averaged $9,100 cumulative over 10 years. Obese adults age 65 and older 
and obese adults with prediabetes experienced the most medical savings—averaging 
$20,550 and $14,110, respectively, over 10 years. Simulated medical benefits among 
these cohorts came from reduced onset of cardiovascular disease, diabetes, and other 
chronic conditions associated with obesity. Subgroups with the lowest savings from 
5% weight loss were the age 20-44 and category I obese groups, averaging $5,800 and 
$7,290, respectively, over 10 years. Weight loss resulted in the largest reduction in dia-
betes incidence in the obese with prediabetes and obese age 20-44 populations, with 
10-year incidence reductions of 19% and 16%, respectively. CONCLUSIONS: Intensive 
lifestyle intervention and other weight loss programs often exceed 5% weight loss, 
generating sizeable medical savings that vary by patient characteristics. Study results 
underscore the importance of reducing excess body weight to prevent new onset of 
disease, and help identify target populations to maximize the medical savings and 
other benefits of weight loss.
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OBJECTIVES: Opioid induced constipation (OIC) is the most common, persistent 
and debilitating side effect reported in patients receiving opioids to manage pain. 
Laxatives are commonly prescribed to treat OIC but in some patients they provide 
inadequate response. Movantik is a peripherally acting mu-opioid receptor antago-
nist used to treat patients with inadequate response to laxative(s) (LIR). A cost effec-
tiveness model was constructed from the UK payer perspective to compare Movantik 
25mg with placebo, rescue laxatives, Relistor and Targin in LIR patients. METHODS: 
Two Phase III 12-week placebo-controlled RCTs, KODIAC 4 and 5, provided data on 
response rates, transition probabilities and EQ-5D inputs for the model for Movantik, 
placebo and rescue laxatives. Tolerability data in the model is generated from both 
these studies and KODIAC 8, a 52-week safety study. The model comprises a decision 
tree for the first 4 weeks of treatment, followed by a Markov model with a 4-week 
cycle length and the following states: non-OIC on treatment, OIC, non-OIC not on 
treatment and death. A mixed treatment comparison provides data on OIC status 
for Relistor and Targin. Resource utilization data used in the model were gathered 
from a UK-based burden of illness study and physician surveys. RESULTS: Movantik 
has an ICER of £10,849 vs. placebo, of £12,639 vs. placebo & rescue laxatives and is 
dominant vs Relistor over a 5 year time horizon in LIR patients. The probabilistic 
OBJECTIVES: To determine healthcare costs among immediate release (IR) hydroco-
done patients diagnosed with opioid abuse compared to those without such diagno-
sis in the United States (US). METHODS: Retrospective analysis using claims from 
the Truven MarketScan® commercial, Medicare supplemental, and Medicaid data-
bases was performed. Patients prescribed IR hydrocodone during the 6-month base-
line period (7/2011-12/2011), and with continuous enrollment during baseline and 
the 12-month follow-up period (2012), were selected. IR hydrocodone patients with 
an ICD-9-CM diagnosis for opioid abuse or dependence (abuse) were identified in 
the follow-up period. Descriptive analyses were employed to compare demographic 
and clinical characteristics between diagnosed opioid abusers and non-abusers. 
Total healthcare costs (standardized to 2013 US dollars) for abusers vs. non-abusers 
during the follow-up were estimated by plan type. Propensity score matching was 
used to estimate incremental costs in the follow-up. RESULTS: A total of 1,743,933 
commercial, 277,096 Medicare, and 157,992 Medicaid IR hydrocodone patients were 
selected. Prevalence of diagnosed opioid abuse for these samples in follow-up was 
0.9%, 0.5%, and 3.2% for commercial, Medicare, and Medicaid, respectively. Among 
commercial patients, unmatched data at baseline showed that abusers had on aver-
age higher co-morbidity burden (0.96 vs. 0.67), and higher pill count (60.8 vs. 20.5 
pills/month) and days’ supply (67.4 vs. 24.1 days) for IR hydrocodone, compared to 
non-abusers. After matching there were no differences in co-morbidity burden (.96 
vs. .99) and pill count (60.8 vs. 60.5) but days’ supply remained significantly different 
(67.4 vs. 63.4). In the matched subset, incremental costs were significantly higher 
among abusers ($14,720, $6,589, and $14,786 for commercial, Medicare, and Medicaid 
patients, respectively) as compared with non-abusers. CONCLUSIONS: IR hydroco-
done patients with diagnosed opioid abuse have higher healthcare costs when com-
pared to matched non-abusers, suggesting significant negative economic impact 
of opioid abuse in the US. Similar trends were observed regardless of plan type.
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OBJECTIVES: Studies have estimated the cost of biologics needed to achieve an addi-
tional responder as measured by Psoriasis Area and Severity Index (PASI) 75and PASI 
90; however, limited information is available including PASI 100. The purpose of this 
analysis was to evaluate the cost per additional responder associated with biologics 
for PASI 75, PASI 90 and PASI 100. METHODS: A literature review was conducted to 
identify randomized controlled trials and meta-analyses that included informa-
tion on PASI 75, PASI 90 or PASI 100 and associated number needed to treat (NNT) 
compared to placebo for adalimumab (ADA), etanercept (ETN), infliximab (IFX), and 
ustekinumab (UST). NNT was calculated as the inverse of absolute risk reduction 
from placebo. The Wholesale Acquisition Costs for each biologic incurred during 
12 weeks of treatment from initiation were determined using Analy$ource® data 
as of November 2014. Administration costs were not included. Cost per additional 
responder was calculated as the NNT multiplied by 12 week drug costs. RESULTS: 
Cost per additional responder for PASI 75 was lowest for ADA ($18,065 - $18,647) 
and IFX ($18,101 - $19,493) followed by UST 45mg ($23,903 - $24,516), ETN ($37,825 
- $41,036), and UST 90mg ($45,048 - $48,418). Cost per additional responder for PASI 
90 was lowest for ADA ($26,805 – $30,418) and IFX ($27,569 - $30,632) followed by UST 
45mg ($38,765 - $39,532), UST 90mg ($71,095 - $88,256) and ETN ($84,749 - $89,209). 
Limited data were available on PASI 100; however, cost per additional responder was 
found to be higher than PASI 75 and PASI 90 based on available data. CONCLUSIONS: 
Cost per additional responder was higher for PASI 90 and PASI 100 given the greater 
NNT for each measure respectively. Understanding the association between costs 
and NNT across various levels of efficacy may be valuable for decision makers when 
evaluating multiple medications.
PSY32
effect of Weight loSS (Wl) on concomitant medication coStS in 
obeSe/overWeight individualS With metabolic SYndrome (metS) 
receiving Phentermine/toPiramate extended-releaSe (Phen/tPm er)
Kahan S.1, Karnawat S.2
1George Washington University School of Public Health and Health Services, Washington, DC, 
USA, 2VIVUS, Inc, Mountain View, CA, USA
OBJECTIVES: Higher healthcare costs are incurred by patients with MetS. WL may 
decrease the risk of MetS and its component comorbidities, thereby reducing medi-
cation use. PHEN/TPM ER treatment, combined with lifestyle interventions, can 
induce WL and reduce incidence of MetS. This post-hoc analysis of a PHEN/TPM ER 
study evaluated annual cost-offsets associated with changes in concomitant medi-
cation use among patients with MetS. METHODS: CONQUER randomized obese/
overweight patients (BMI ≥ 27 -≤ 45kg/m2) with ≥ 2 weight-related comorbidities to 
placebo (n= 994), PHEN 7.5mg/TPM ER 46mg (7.5/46; n= 498), or PHEN 15mg/TPM ER 
92mg (15/92; n= 995). MetS was defined as presence of ≥ 3 of the following risk fac-
tors: waist circumference ≥ 102cm (men), ≥ 88cm (women); triglycerides ≥ 150mg/dL; 
HDL-cholesterol < 40mg/dL (men), < 50mgl/dL (women); systolic blood pressure (BP) 
≥ 130mmHg or diastolic BP ≥ 85mmHg; and fasting glucose ≥ 100mg/dL. This analysis 
included patients with MetS using ≥ 1 concomitant medication at baseline or end of 
treatment (EOT) for hypertension, dyslipidemia, or type 2 diabetes. Cost-offsets (±SD) 
in antihypertensive, lipid-lowering, and antidiabetic medication use were calculated 
by multiplying unit cost (Medi-Span’s PriceRx) by number of doses per day from 
baseline to Week 56/EOT. PHEN/TPM ER cost was not included. RESULTS: In total, 349 
patients receiving placebo, 184 receiving 7.5/46, and 359 receiving 15/92, had MetS at 
baseline and received ≥ 1 concomitant medication. At baseline, mean weight (±SD) 
was 105±18kg among all patients. Baseline annual concomitant medication costs 
were $1222±1450, $1306±1401, and $1303±1348 for placebo, 7.5/46, and 15/92, respec-
tively. At EOT, mean percent WL was -1.9%, -8.6%, and -10.5%, respectively (P< .0001 
vs placebo). At EOT, annual concomitant medication costs increased with placebo 
and decreased with PHEN/TPM ER: $36±33 (+3%), -$83±46 (-6%), and -$103±33 (-8%), 
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model from the perspective of a US private insurance payer to evaluate the cost-
effectiveness of rituximab, tacrolimus, and cyclosporine in a hypothetical cohort 
of 1,000 patients with refractory MG, aged 20 years and above. We obtained dis-
ease transition probabilities, costs and outcomes data from the published litera-
ture. We calculated the incremental cost-effectiveness ratios (ICERs) as cost per 
quality-adjusted life-year (QALY) gained and cost per myasthenic crisis averted 
after the first two years of treatment and over a patient’s lifetime. RESULTS: In 
the first two years after treatment rituximab is not cost-effective compared with 
cyclosporine, given an ICER of $368,823 per QALY gained. However, over a patient’s 
lifetime rituximab has an ICER of $41,947 per QALY gained making it more cost-
effective than cyclosporine in the context of the commonly accepted US thresh-
old of $50,000 per QALY gained. Tacrolimus is more costly and less effective 
than cyclosporine and rituximab both after two years of treatment and over a 
 patient’s lifetime. CONCLUSIONS: Assuming the benefits of treatment persist over 
time, rituximab is more cost-effective than cyclosporine over a patient’s lifetime but 
not after two years of treatment under both the standard US threshold of $50,000 
per QALY gained and an alternative higher threshold of $100,000 per QALY gained. 
Additional research is needed to evaluate the long-term benefits of rituximab.
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OBJECTIVES: Nearly 54 million Medicare beneficiaries, the overwhelming majority 
of whom are 65 plus years of age, reside in the US. Many beneficiaries suffer from 
chronic pain and need to use opioid analgesics for treatment. Medicare Part D is 
the outpatient prescription drug benefit available to beneficiaries through private 
insurance companies. Plan offerings differ across the country and each plan can 
have a different cost-sharing structure and formulary. We sought to examine the 
cost differences between therapeutically equivalent doses of opioid analgesics 
across all Medicare Part D Stand-alone prescription drug plans (PDPs). METHODS: 
Five short- and five long-acting opioid analgesic drugs were selected based on 
their prevalence of use and effectiveness at treating chronic pain. Therapeutically 
equivalent doses of each drug were entered into the Medicare Plan Finder Tool 
(www.medicare.gov) and 2015 data from 965 PDPs in 34 Medicare regions across the 
country were recorded. Collected data for each drug included: full cost, expected 
out-of-pocket costs both in a retail and mail order setting, and cost at a stand-
ard and preferred network pharmacy. RESULTS: Full annual retail drug costs var-
ied from a low of $134.42 (Methadone 5mg; thrice daily) to a high of $10,443.30 
(Hydromorphone ER 16mg; once daily). Beneficiary cost-sharing of the full annual 
drug costs in a retail pharmacy ranged from 36% (Hydrocodone 5/325; 12 tabs daily) 
to 93% (Hydromorphone ER). The annual out-of-pocket costs through mail order 
were between 88% (Oxycodone 5mg; 8 tabs daily) and 102% (Morphine 30mg; 2 
tabs daily) of the costs in a retail pharmacy setting. Beneficiary out-of-pocket costs 
for the same drug was between 7% and 44% cheaper at a preferred network phar-
macy as compared to a standard network pharmacy. CONCLUSIONS: Considerable 
cost variability exists among equipotent opioid analgesics across Medicare PDPs. 
Minimizing beneficiary out-of-pocket costs may improve economic outcomes with-
out sacrificing clinical outcomes.
PSY41
forecaSting the united StateS lifetime coSt and outcomeS of 
ivacaftor in PatientS With cYStic fibroSiS
Dilokthornsakul P., Campbell J.D.
University of Colorado Anschutz Medical Campus, Denver, CO, USA
OBJECTIVES: Ivacaftor is a breakthrough treatment for cystic fibrosis (CF) patients 
with the G551D genetic mutation. Clinical trials show ivacaftor significantly 
improves lung function. Information on lifetime clinical effects and cost are lacking. 
This study aims to forecast lifetime outcomes and cost by comparing ivacaftor plus 
usual care versus usual care alone. METHODS: A lifetime Markov model of ivacaftor 
for G551D mutation CF patients aged ≥ 6 years was conducted from a United States 
payer perspective. The model consisted of 5 health states: 1) forced expiratory vol-
ume 1-second (FEV1) % predicted > 70%, 2) 40%≤ FEV1≤ 70%, 3) FEV1< 40%, 4) Lung 
transplantation, and 5) Death. All inputs were determined by literature sources. 
Efficacy of ivacaftor was from previous randomized clinical trials for the first 2 years. 
The efficacy after 2 years was assumed half of the observed efficacy (consistent 
with United Kingdom assessment assumption). The budget impact was estimated. 
We indirectly estimated ivacaftor’s improvement in CF outcome gaps compared 
to the non-CF population. RESULTS: Compared to the usual care alone, ivacaftor 
treatment was associated with 18.09 additional life-years [(95% credible interval 
(CI); 14.63-21.13] and 14.92 additional quality-adjusted life-years (QALYs) [95%CI; 
11.92 – 17.95] over an average lifetime. Moving from usual care alone to ivacaftor 
treatment was associated with reducing the survival and QALY gaps of the non-CF 
population by 52.32% and 44.29%, respectively. The incremental lifetime cost with 
3% discount was $3,740,480. The budget impact was $0.09 per-member per-month 
[95% CI; $0.07 to $0.11]. CONCLUSIONS: Ivacaftor was forecasted to increase life-
years and QALYs in CF patients with the G551D mutation and move morbidity 
and mortality outcomes closer to that of their non-CF peers. The overall cost in 
patients with ivacaftor is much higher than usual care, but comes at a relatively low 
budget impact. Uncertainty in this literature-informed analysis could be reduced 
with patient-level analyses.
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sensitivity analyses indicates that for these comparisons, based on a threshold of 
£20,000, Movantik has a respective probability of 91%, 83% and 100% of being cost 
effective. In a population of LIR patients who are taking step 3 opioids, Movantik is 
dominant vs. Targin over a 5 year time horizon. CONCLUSIONS: Movantik is a cost-
effective treatment option for patients with OIC who have experienced inadequate 
response to laxative(s).
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OBJECTIVES: Limbal Stem Cell Deficiency (LSCD) is a rare condition characterized by 
the shortage of limbal stem cells in the eye resulting in corneal conjunctivalization, 
corneal opacity, visual impairment and even blindness. Recently, the first advanced 
therapy medicinal product (ATMP) containing stem cells (GPLSCD01) has been rec-
ommended for approval by EMA in moderate-severe LSCD due to chemical or physi-
cal burn. A Cost Effectiveness Analysis (CEA) was performed, from a public payer 
perspective, to compare GPLSCD01 in LSCD with conservative treatment, given that, 
currently, no other medicinal product is approved for this disease. METHODS: We 
analyzed visual acuity and symptoms from 99 patients (average age 46.8 yrs.) treated 
with GPLSCD01; data were taken from a retrospective, case-series, non-randomized, 
non-controlled, multicenter clinical study (HLSTM01), covering up to 10 years fol-
low-up. LSCD-impaired visual acuity and symptoms such as pain, burning and 
photophobia were used in the model to assess the QoL associated with the condi-
tion, and Quality Adjusted Life Years (QALY) to compare the outcomes of GPLSCD01 
treatment versus conservative management, in a similar patient pool. RESULTS: 
Patients under conservative treatment had between 10.29 and 17.24 QALYs, depend-
ing on LSCD severity, whereas patients treated with GPLSCD01 showed between 
15.93 and 22.49 QALYs, with a total utility gain between 5.25 and 6.04 QALYs in the 
GPLSCD01 group, this result being already discounted by 3.0%, in compliance with 
National Institute for Health Care Excellence (NICE) guidelines. Due to the utility 
gain, GPLSCD01 would meet NICE conventional ICER thresholds (20,000 – 30,000 GBP/
QALY) up to a treatment cost of 150,000 GBP. CONCLUSIONS: GPLSCD01 is a regen-
erative medicine, offering long-term, potentially life-long effectiveness after single 
administration. This CEA shows that GPLSCD01 in moderate-severe LSCD provides a 
significant gain in QALYs compared to conventional, conservative management of 
the condition, balancing, from a payer perspective, initial higher acquisition costs.
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OBJECTIVES: The cost of lost productivity associated with chronic fatigue has 
been estimated to be more than £75 million per year in the U.K. Cognitive behav-
ioral Therapy (CBT) based fatigue self-management (FSM) has been shown to 
be effective in reducing fatigue symptoms. This study aimed to examine the 
cost-effectiveness of a home-based CBT-FSM intervention as compared to usual 
care. METHODS: 137 Primary care patients between 18 and 65 years of aging who 
had at least six months of persistent fatigue were randomized into either home-
based CBT-FSM intervention (n= 89, 45 with actigraph and web diaries and 44 with 
pedometer and paper diaries) or usual care (n= 48). All patients were followed for 12 
months post-treatment. Effectiveness was measured by the Fatigue Severity Scale 
(FSS) and health care resource use was measured by a utilization diary. Resource 
use categories included provider visits, diagnostic tests, prescription medication 
use, and use of emergency room, hospital, informal care, and days of lost work. We 
used ordinary least squares model and generalized linear model to estimate the 
treatment effect on effectiveness and health care expenditures, respectively. Cost-
effectiveness was measured by the incremental cost-effectiveness ratio (ICER) and 
net monetary benefit. RESULTS: The sample had a mean age of 48.5 years and 
most patients were female (88.3%). Baseline characteristics were similar between 
the intervention and control groups. Adjusting for baseline characteristics, the 
intervention had a small non-significant effect on FSS (-0.16, p= 0.32) and total 
expenditures (0.09, p= 0.32), resulting an ICER of 388 (bootstrapped 95% CI: -16463, 
17239). Cost-effectiveness acceptability curve showed that CBT-FSM had an 85% 
probability of being cost-effective if societal willingness-to-pay for each 1 point 
reduction on the FSS. CONCLUSIONS: The intervention did not appear to be cost-
effective as compared to usual care. The home-based intervention needs to be 
modified to maintain effectiveness achieved in prior interventions delivered by 
training professionals.
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OBJECTIVES: Myasthenia gravis (MG) is a rare autoimmune disorder characterized 
by exacerbations and remissions. The costs of managing MG are higher than those 
of many other chronic neurological diseases and there are no studies evaluating 
the cost-effectiveness of treatment alternatives for refractory MG in patients who 
failed to respond to at least two successive immunosuppressive drugs. This study 
aimed to assess the incremental costs and benefits of rituximab, cyclosporine, 
and tacrolimus in the treatment of refractory MG. METHODS: We used a Markov 
